87 results
SC 14D9
PNT
POINT Biopharma Global Inc.
13 Oct 23
Tender offer solicitation
7:11am
(including the topline data results from
the SPLASH trial), availability of third-party reimbursement, success of POINT’s ongoing collaboration
SC TO-T
EX-99
PNT
POINT Biopharma Global Inc.
13 Oct 23
Third party tender offer statement
6:52am
, reimbursement or insurance coverage thereof,
except (x) in the case of clauses (A), (B), (C), (D) or (E), to the extent that POINT and the POINT
SC14D9C
EX-2.1
PNT
POINT Biopharma Global Inc.
3 Oct 23
Written communication relating to third party tender offer
7:37am
Subsidiary, or the pricing, reimbursement or insurance coverage thereof, except (x) in the case of clause (A), (B), (C), (D) or (E), to the extent … or arrangement that provides for the gross-up or reimbursement of Taxes imposed under Section 409A or 4999 of the Code (or any corresponding provisions
8-K
EX-2.1
PNT
POINT Biopharma Global Inc.
3 Oct 23
Tender and Support Agreement
7:35am
Subsidiary, or the pricing, reimbursement or insurance coverage thereof, except (x) in the case of clause (A), (B), (C), (D) or (E), to the extent … or arrangement that provides for the gross-up or reimbursement of Taxes imposed under Section 409A or 4999 of the Code (or any corresponding provisions
ARS
lklhbh c9gsy72aoa29a
1 May 23
Annual report to shareholders
1:52pm
8-K
EX-1.1
uf467ckl158ewc68n8
14 Sep 22
POINT Biopharma Prices Public Offering of Common Stock
4:14pm
424B5
t625y7 11p
14 Sep 22
Prospectus supplement for primary offering
4:12pm
424B5
1epmd
13 Sep 22
Prospectus supplement for primary offering
5:19pm
424B3
72rxyznc98ntdi sq7ba
11 Jul 22
Prospectus supplement
4:32pm
POS AM
yhmfb0et2 aji
1 Jul 22
Prospectus update (post-effective amendment)
4:17pm
S-3
EX-4.6
w5ui3
1 Jul 22
Shelf registration
4:13pm
S-3
EX-4.7
pg16p9zgjsmucfios
1 Jul 22
Shelf registration
4:13pm